去年，Edwards Lifesciences Corp表現最佳的業務類別Transcatheter Aortic Valve Replacement的營收達到4.49B美元。United States的營收貢獻最高，去年達到3.54B美元。最近一個季度，截至2026-06-30，Edwards Lifesciences Corp表現最佳的業務類別Transcatheter Aortic Valve Replacement的營收達到1.26B美元。United States的營收貢獻最高，達到1.00B美元。

業務

營業收入

佔比

年報

年報

單季報

Transcatheter Aortic Valve Replacement

Surgical Heart Valve Therapy

Transcatheter Mitral and Tricuspid Therapies

Critical Care

Transcatheter Heart Valve Therapy

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Transcatheter Aortic Valve Replacement

4.49B(73.96%)

4.11B(75.49%)

3.88B(65.34%)

3.52B(66.14%)

3.42B(65.41%)

2.86B(65.14%)

2.74B(62.97%)

--(--)

Surgical Heart Valve Therapy

1.03B(16.96%)

981.30M(18.04%)

932.60M(15.71%)

829.70M(15.60%)

889.10M(16.99%)

761.80M(17.37%)

841.70M(19.36%)

761.60M(20.46%)

807.10M(23.49%)

774.90M(26.15%)

785.00M(31.48%)

Transcatheter Mitral and Tricuspid Therapies

550.60M(9.07%)

352.10M(6.47%)

197.60M(3.33%)

116.10M(2.18%)

86.00M(1.64%)

41.80M(0.95%)

28.20M(0.65%)

--(--)

Critical Care

--(--)

928.10M(15.63%)

855.00M(16.07%)

834.90M(15.96%)

725.40M(16.54%)

740.20M(17.02%)

674.50M(18.12%)

601.00M(17.49%)

560.30M(18.91%)

528.40M(21.19%)

Transcatheter Heart Valve Therapy

--(--)

2.29B(61.42%)

2.03B(59.01%)

1.63B(54.95%)

1.18B(47.33%)

地區

營業收入

佔比

年報

年報

單季報

United States

Europe

Rest of the world

Japan

Unallocated

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

3.54B(58.39%)

3.21B(58.94%)

2.95B(58.84%)

2.63B(58.88%)

2.96B(56.63%)

2.52B(57.38%)

2.53B(58.25%)

Europe

1.52B(25.01%)

1.32B(24.30%)

1.18B(23.56%)

1.04B(23.30%)

1.19B(22.75%)

945.20M(21.55%)

926.10M(21.30%)

Rest of the world

652.30M(10.75%)

572.00M(10.52%)

531.10M(10.60%)

436.00M(9.77%)

550.20M(10.52%)

451.50M(10.29%)

433.30M(9.97%)

Japan

354.70M(5.85%)

339.80M(6.25%)

350.80M(7.00%)

359.50M(8.05%)

528.90M(10.11%)

448.60M(10.23%)

441.40M(10.15%)

Unallocated

--(--)

24.20M(0.55%)

14.50M(0.33%)